FDA, EMA Accept Filings for Teva Xolair Biosimilar
The US FDA and the European Medicines Agency (EMA) accepted regulatory filings for Teva Pharma's biosimilar candidate to Xolair (omalizumab).
Tag: Teva Pharma
All
Latest
FDA, EMA Accept Filings for Teva Xolair Biosimilar
The US FDA and the European Medicines Agency (EMA) accepted regulatory filings for Teva Pharma’s biosimilar candidate to Xolair (omalizumab).
Read More
FDA Approves Albuterol Sulfate Inhalation Aerosol from Amneal
Amneal Pharma’s new albuterol sulfate inhalation aerosol offers a generic equivalent for Teva’s ProAir HFA.
Read More
Do Transparent Capsule Inhalers Improve Medication Delivery?
Researchers investigated whether transparent capsules in dry powder inhalers improved medication delivery by providing visual feedback to patients.
Read More
FDA Approves Amphastar’s Generic Albuterol Sulfate
The FDA approved Amphastar’s abbreviated new drug application for its albuterol sulfate inhalation aerosol, a generic for Teva’s ProAir HFA.
Read More
AAFA Applauds Senate Investigation into Asthma Inhaler Pricing
AAFA says the investigation opens an opportunity to address what patients report as the primary reason why people don’t adhere to their asthma treatment: the cost of prescribed asthma medication.
Read More
Teva Releases AirDuo RespiClick plus Generic for Asthma
The AirDuo RespiClick and its authorized generic will directly compete with GlaxoSmithKline’s Advair for the treatment of asthma.
Read MoreTeva’s Severe Asthma Therapy Reslizumab Now Approved in Europe
Teva’s Cinqaero (reslizumab) has been approved in the EU to treat adults with severe eosinophilic asthma inadequately controlled despite high-dose inhaled corticosteroids.
Read More
FDA Expands Approval of ProAir RespiClick to Children 4 to 11
Teva’s ProAir RespiClick (albuterol sulfate) Inhalation Powder is approved to treat bronchospasm in children 4 to 11 years of age with asthma and prevent exercise-induced bronchospasm.
Read More
FDA Panel Backs Reslizumab for Adults With Severe Asthma
Reslizumab has been recommended for approval by an FDA advisory committee for use in treating adults 18 years and older with asthma.
Read MorePositive Asthma Results for Teva’s Multidose Dry Powder Inhalers
Teva Pharmaceuticals announced positive results from Phase III trials that tested the safety and efficacy of multi dose dry power inhalers in adolescent and adult patients with asthma.
Read More
Teva Pharmaceuticals Buys Smart Inhaler Company Gecko Health Innovations
Teva Pharmaceuticals has announced it will acquire Gecko Health Innovations, a smart inhaler company.
Read More